0.4901
price up icon0.02%   0.000100
 
loading
前日終値:
$0.49
開ける:
$0.49
24時間の取引高:
14,244
Relative Volume:
0.25
時価総額:
$10.12M
収益:
$2.82M
当期純損益:
$-14.20M
株価収益率:
-0.5766
EPS:
-0.85
ネットキャッシュフロー:
$-15.13M
1週間 パフォーマンス:
-0.69%
1か月 パフォーマンス:
-22.78%
6か月 パフォーマンス:
-47.86%
1年 パフォーマンス:
-47.30%
1日の値動き範囲:
Value
$0.49
$0.5099
1週間の範囲:
Value
$0.453
$0.51
52週間の値動き範囲:
Value
$0.45
$1.27

Talphera Inc Stock (TLPH) Company Profile

Name
名前
Talphera Inc
Name
セクター
Healthcare (1155)
Name
電話
650-216-3500
Name
住所
1850 GATEWAY DRIVE, SAN MATEO
Name
職員
13
Name
Twitter
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
TLPH's Discussions on Twitter

TLPH を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
TLPH
Talphera Inc
0.495 10.12M 2.82M -14.20M -15.13M -0.85
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
149.41 66.56B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.45 45.61B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.29 45.01B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
13.93 15.25B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
291.62 12.79B 2.76B 1.11B 898.10M 22.77

Talphera Inc Stock (TLPH) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-28 開始されました Rodman & Renshaw Buy
2020-07-20 ダウングレード Credit Suisse Neutral → Underperform
2019-11-11 ダウングレード Credit Suisse Outperform → Neutral
2019-08-05 再開されました Credit Suisse Outperform
2019-07-10 再開されました Credit Suisse Outperform
2019-04-24 再開されました B. Riley FBR Buy
2019-02-15 開始されました Credit Suisse Outperform
2018-10-23 開始されました B. Riley FBR Buy
2017-10-13 ダウングレード Jefferies Buy → Hold
2017-10-13 繰り返されました RBC Capital Mkts Outperform
2017-07-14 再開されました Jefferies Buy
2016-09-15 繰り返されました ROTH Capital Buy
2016-08-05 ダウングレード Stifel Buy → Hold
2015-10-30 アップグレード Jefferies Hold → Buy
2015-10-05 繰り返されました ROTH Capital Buy
2015-09-02 開始されました H.C. Wainwright Buy
2015-07-10 再開されました ROTH Capital Buy
2015-05-06 繰り返されました Mizuho Neutral
2015-05-05 繰り返されました RBC Capital Mkts Outperform
2015-03-10 繰り返されました RBC Capital Mkts Outperform
2015-03-09 ダウングレード Mizuho Buy → Neutral
すべてを表示

Talphera Inc (TLPH) 最新ニュース

pulisher
Apr 05, 2025

HC Wainwright Predicts Talphera’s Q1 Earnings (NASDAQ:TLPH) - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

HC Wainwright Estimates Talphera FY2029 Earnings - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com

Apr 03, 2025
pulisher
Apr 02, 2025

Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Talphera: Q4 Earnings Snapshot - CT Insider

Apr 01, 2025
pulisher
Apr 01, 2025

Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Talphera Reports 2024 Financial Results and Study Update - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK

Mar 31, 2025
pulisher
Mar 31, 2025

TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

TALPHERA, INC. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

FDA approves Talphera’s reduced NEPHRO CRRT study size - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Talphera reports Q4 EPS (7c) vs. (25c) last year - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

FDA Green Light: Talphera Slashes Trial Size by 58% as Q4 Losses Drop 57% - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

TLPH stock touches 52-week low at $0.5 amid market challenges - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Talphera to Reduce Size of Renal Replacement Therapy Study, Enters Private Placement; Shares Fall - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million - PR Newswire

Mar 31, 2025
pulisher
Mar 28, 2025

Earnings Outlook For Talphera - Benzinga

Mar 28, 2025
pulisher
Mar 26, 2025

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 - Longview News-Journal

Mar 26, 2025
pulisher
Mar 26, 2025

Talphera to Unveil 2024 Performance: Key Financial Results and Strategic Updates Coming March 31 - Stock Titan

Mar 26, 2025
pulisher
Mar 14, 2025

Talphera Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView

Mar 14, 2025
pulisher
Mar 03, 2025

Talphera (TLPH) Expected to Announce Earnings on Wednesday - Defense World

Mar 03, 2025
pulisher
Feb 27, 2025

Talphera chief medical officer Aslam Shakil purchases $6,038 in stock By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 26, 2025

Talphera chief medical officer Aslam Shakil purchases $6,038 in stock - Investing.com

Feb 26, 2025
pulisher
Feb 22, 2025

Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened - Armenian Reporter

Feb 22, 2025
pulisher
Feb 17, 2025

Talphera Inc (NASDAQ: TLPH) Is On The Rise - Stocks Register

Feb 17, 2025
pulisher
Jan 30, 2025

RODMAN&RENSHAW Upgrades Talphera (NASDAQ:TLPH) to Strong-Buy - Defense World

Jan 30, 2025
pulisher
Jan 28, 2025

Rodman & Renshaw sets Talphera stock Buy rating, $4 target - MSN

Jan 28, 2025
pulisher
Jan 22, 2025

Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright - Defense World

Jan 22, 2025
pulisher
Jan 14, 2025

FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada

Jan 14, 2025
pulisher
Jan 14, 2025

FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

FDA to review Talphera's request to amend NEPHRO study - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - The Eastern Progress Online

Jan 14, 2025
pulisher
Dec 26, 2024

TLPH stock touches 52-week low at $0.6 amid market shifts - Investing.com UK

Dec 26, 2024
pulisher
Dec 17, 2024

TLPH stock touches 52-week low at $0.61 amid market challenges - Investing.com

Dec 17, 2024
pulisher
Dec 12, 2024

Talphera faces Nasdaq delisting over share price rule - Investing.com

Dec 12, 2024
pulisher
Dec 11, 2024

Talphera faces Nasdaq delisting over share price rule By Investing.com - Investing.com UK

Dec 11, 2024
pulisher
Dec 11, 2024

Acelrx Announces Dsuvia® Milestone C Approval; Provides Revenue Guidance for the First Quarter 2020 - Marketscreener.com

Dec 11, 2024

Talphera Inc (TLPH) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Talphera Inc (TLPH) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Aslam Shakil
Chief Medical Officer
Jun 14 '24
Buy
1.07
5,000
5,357
37,695
Aslam Shakil
Chief Medical Officer
Jun 13 '24
Buy
0.98
695
681
32,695
Angotti Vincent J.
CHIEF EXECUTIVE OFFICER
Dec 05 '24
Buy
0.64
5,000
3,200
208,066
ASADORIAN RAFFI
Chief Financial Officer
Dec 02 '24
Sale
0.77
155
119
37,578
Angotti Vincent J.
CHIEF EXECUTIVE OFFICER
Nov 27 '24
Buy
0.73
5,000
3,650
203,066
$8.64
price up icon 1.71%
$27.39
price up icon 0.81%
$101.32
price up icon 0.62%
$7.66
price up icon 0.92%
$102.22
price up icon 0.76%
$289.83
price up icon 1.60%
大文字化:     |  ボリューム (24 時間):